Free Trial

Iterum Therapeutics Q2 2024 Earnings Report

Iterum Therapeutics logo
$1.18 -0.05 (-3.66%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Iterum Therapeutics EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Iterum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Iterum Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Iterum Therapeutics Earnings Headlines

Iterum Therapeutics Appoints New Board Members
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
See More Iterum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iterum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iterum Therapeutics and other key companies, straight to your email.

About Iterum Therapeutics

Iterum Therapeutics (NASDAQ:ITRM), a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

View Iterum Therapeutics Profile

More Earnings Resources from MarketBeat